card game questions for friends

card game questions for friends Elon Musk seemingly admitted to using an Ozempic-like weight loss drug while posing as Santa Claus next to a Christmas tree in his latest holiday post. Musk has been quite vocal in his support for GLP-1 drugs or weight loss drugs like Ozempic, Zepbound, Mounjaro, and Wegovy. In December, Musk, now a prominent figure in US politics, posted on X, saying: "Nothing would do more to improve the health, lifespan, and quality of life for Americans than making [GLP-1 drugs] super low cost to the public. Nothing else is even close." Katy Perry weighs in on how she got her figure after Ozempic rumors Brooks Nader’s sister calls her out over Ozempic use in TikTok roast His views, however, contrast with Robert F. Kennedy Jr., President-elect Donald Trump 's nomination for the Department of Health and Human Services lead. Musk, the CEO of Tesla and Space X, suggested that he takes Mounjaro, a drug that treats type-2 diabetes by lowering a person's blood sugar levels. Ozempic Santa pic.twitter.com/7YECSNpWoz — Elon Musk (@elonmusk) December 26, 2024 As he posed next to a Christmas tree, Musk wrote: "Ozempic Santa." In his replies, he said: "Like Cocaine Bear, but Santa and Ozempic! Technically, Mounjaro, but that doesn't have the same ring to it." Mounjaro was approved by the Food and Drug Administration under the brand name Zepbound in November 2023 to serve as a weight management drug for people who are struggling with obesity. Following his nomination, RFK Jr. criticized how almost 9 million prescriptions are allegedly been written every year prescribing weight loss drugs like Ozempic on Greg Gutfeld's late-night show. "We are spending $1.6k a month on this drug. There is a bill right now before Congress that will make it available to everybody who is overweight... that alone will cost $ 3 trillion a year," he said. RFK Jr. argued that if the US spends "about one-fifth of that" catering to providing "good food" to Americans, the "obesity and diabetes epidemic" can be solved "overnight." Following his public decry in November, RFK Jr., however, changed his views slightly in December, a day after Musk voiced his public support for the drug. When asked about the same in a CNBC interview at the New York Stock Exchange the day Trump was invited to ring the opening bell, RFK Jr. was milder in his rhetoric. "The first line of response should be lifestyle. It should be eating well, making sure you that you don’t get obese, and that those GLP drugs have a place," he said. Trump has been in the hot seat amid Ozempic usage rumors that have not spared celebrities who have recently lost a lot of weight. Musk, one of Trump's strongest allies and the biggest donor to Trump's cause who spent more than a quarter of a billion dollars to help orchestrate Trump's win has been a constant fixture in the President-elect's Mar-a-Lago estate. He is also set to head the Department of Government Efficiency with Vivek Ramaswamy to hold the US government accountable in their spending and budget. Democrats and social media users have criticized Musk's looming presence, suggesting that he is pulling the strings. Trump recently laid rest to those rumors while speaking at the conservative Turning Point USA’s annual AmericaFest conference. "No, he’s not going to be president, that I can tell you," Trump shared with the crowd in Phoenix on Sunday, adding: "And I’m safe. You know why he can’t be? He wasn’t born in this country."

Deep-pocketed investors have adopted a bearish approach towards Lam Research LRCX , and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LRCX usually suggests something big is about to happen. We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for Lam Research. This level of activity is out of the ordinary. The general mood among these heavyweight investors is divided, with 30% leaning bullish and 40% bearish. Among these notable options, 12 are puts, totaling $585,068, and 8 are calls, amounting to $1,196,232. Projected Price Targets Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $54.0 to $164.0 for Lam Research over the last 3 months. Analyzing Volume & Open Interest In today's trading context, the average open interest for options of Lam Research stands at 793.58, with a total volume reaching 4,701.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Lam Research, situated within the strike price corridor from $54.0 to $164.0, throughout the last 30 days. Lam Research Option Activity Analysis: Last 30 Days Biggest Options Spotted: Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume LRCX CALL TRADE BEARISH 06/20/25 $5.45 $5.15 $5.25 $85.00 $787.5K 627 1.5K LRCX CALL SWEEP BULLISH 02/21/25 $8.85 $8.75 $8.85 $68.00 $172.5K 72 0 LRCX PUT TRADE NEUTRAL 01/03/25 $10.95 $10.75 $10.84 $85.00 $54.2K 0 350 LRCX PUT SWEEP BULLISH 01/16/26 $93.7 $89.65 $90.05 $164.00 $54.0K 0 6 LRCX PUT TRADE NEUTRAL 01/03/25 $11.15 $10.4 $10.8 $85.00 $54.0K 0 200 About Lam Research Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron. Lam Research's Current Market Status With a trading volume of 2,523,239, the price of LRCX is up by 0.7%, reaching $74.35. Current RSI values indicate that the stock is may be approaching overbought. Next earnings report is scheduled for 27 days from now. What The Experts Say On Lam Research 3 market experts have recently issued ratings for this stock, with a consensus target price of $82.0. Turn $1000 into $1270 in just 20 days? 20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access .* An analyst from Wells Fargo persists with their Equal-Weight rating on Lam Research, maintaining a target price of $83. * An analyst from Bernstein has decided to maintain their Market Perform rating on Lam Research, which currently sits at a price target of $85. * Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Lam Research with a target price of $78. Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Lam Research options trades with real-time alerts from Benzinga Pro . © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Mum died after hospital staff made paracetamol mistake as coroner rejects 'natural causes'

JEOPARDY! champion Laura Faddah has blown fans away with an ‘improbable’ winning streak after ‘getting lucky’ with various advantages. The game show contestant was praised for being “relatable” to at-home viewers despite her impressive knowledge giving her one of the longest winning streaks of season 41 . On Thursday’s game, the Memphis Tennessee native was looking to extend her five-day winnings of $58,400. Laura, who is a manager at the Berkeley Research Group went up against Brad Grusnick, a voice actor from Aurora, Illinois and Carole Portas Keane, an education researcher from New Jersey. The game started off on a bad note for Brad - who lost his entire $2,400 fortune on a true Daily Double despite securing an early lead. Heading into the Double Jeopardy! round, Laura already secured $4,000 while Carole was closely behind with $3,400 and Brad followed with $2,400. READ MORE ON JEOPARDY! Laura found the game’s second Daily Double as host Ken Jennings read the $1,200 clue under the category “Differing by a Letter.” “Treat with pharmaceuticals & engage in a practice to achieve calmness & enlightenment,” Ken read. Laura correctly responded with “what are mediate and meditate?” - adding $1,600 to her large lead after an impressive run at the beginning of the Double Jeopardy! round. Carole, who was now in a distant third place, found the last Daily Double and bet her entire fortune in an attempt to get her score closer to her opponents. Most read in Game shows “James Gadsden negotiated with this Mexican pres. whom Texans had met in battle; the purchase helped get him ousted from office,” Ken read under the “The Gadsden Purchase” category. She correctly answered with “Who Was Santa Anna?” - doubling her score to $6,400. Heading into Final Jeopardy!, Laura had the most amount she’s had during her run with $20,400. Brad was in a distant second with $9,200 while Carole added $6,400 to her prize pot. Ken introduced the last category “Movies & Their Soundtracks” while the players placed their wagers. “‘Catch it’ was a tagline for this film whose iconic soundtrack became one of the bestselling albums of all time,” the host read. All three players were correct with their guess of the iconic 1977 John Travolta classic, What is Saturday Night Fever? Laura, like she has done in past games, wagered very conservatively - placing her final total at $21,000. Carole ended with $9,400 while Brad bet $0, ending with $9,200. ALL BETS ARE OFF Laura is one of the few contestants of season 41 who has broken through winning five games - securing her spot at the Tournament of Champions. Fans were impressed by the manager’s winning streak - even if they partially credited “luck” being a factor as to why she’s been able to make it this far. One viewer wrote: “Laura’s run as champion is a great example of what has made the show popular over all these decades. “A regular person who, through a combination of smarts and some luck, has gone on an improbably long run where we can't wait to see what happens next. “The home viewer can easily relate to Laura and imagine themselves up there in the same position. This is Jeopardy!, and many of us will miss it when the show returns to its overblown ‘post-season.’” Jeopardy!'s next Tournament of Champions will take place this winter, midway through Season 41 (exact airdate TBA) and it's shaping up to be another showstopper. Here's who is officially eligible so far: Adriana Harmeyer (15 wins and $349,600 total) Isaac Hirsch (nine wins and $215,390) Greg Jolin (five wins and $135,002) Survivor alum Drew Basile (seven wins and $129,601) Alison Betts (5 wins and $121,500) Mark Fitzpatrick (five wins and $107,201) Dr. Amy Hummel (5 wins and $100,994) Ryan Manton (four wins and $83,179) Grant DeYoung (four wins and $81,203) Will Wallace (four wins and $79,998) Amar Kakirde (four wins and $55,899) Lisa Ann Walter (winner of Celebrity Jeopardy! 2024) The prize for winning the ToC is $250,000 and a coveted slot in Jeopardy! Masters. Jeopardy.com notes: "All 4-time and over winning players starting from 04/10/24 will be eligible for a future Tournament of Champions." "Presence on this list does NOT guarantee an invitation to compete. Other eligibility rules apply and final selection is up to the producers' sole discretion." Another agreed, insisting: “Laura continues to impress. She's caught some lucky breaks along the way, but you can't put together a 6-game win streak solely on luck. “According to the box scores, she's had more buzzer attempts than either of her opponents since her 3rd game, so she clearly knows her stuff. “And she looked relaxed and dominant in today's game (the 4th of the taping day), which takes serious stamina.” Someone else replied, adding: “100% this. Yes she’s caught some lucky breaks but you have to be good to be in a position to take advantage of those breaks!” Read More on The US Sun While one more shared a similar sentiment: “Laura is getting better. She's had some luck along the way to the ToC, for sure, but today's win was her largest prize yet. “Now that she's made it past her qualification, I wouldn't be at all surprised to see her continue improving and end up with 10+ wins.”imaginima In a previous article , I discussed OpenAI's "o3" breakthrough and its profound impact on Nvidia ( NVDA ). Readers seemed to appreciate the overview of the science behind "o3" and its implications on Nvidia. Building on that foundation, I will dive deeper into the Analyst’s Disclosure: I/we have a beneficial long position in the shares of NVDA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

( ) shares are under pressure on Tuesday morning. At the time of writing, the ASX 200 stock is down 10% to $19.78. Why is this ASX 200 stock tumbling? Investors have been selling the financial services company's shares today after a from the Australian Taxation Office (ATO) cast doubts on the $2.175 billion sale of its Wealth Management and Corporate Trust businesses to KKR. According to the release, following ongoing and extensive engagement with the ATO, Perpetual has now received written views from the tax office. This is in relation to the tax treatment of the transaction that inform Perpetual's updated assessment of the estimated net cash proceeds to shareholders, if the scheme is implemented. The ATO has informed Perpetual that section 45B of the Income Tax Assessment Act of 1936 would apply to the scheme. This would mean that the entire cash return would be deemed to be an assessable unfranked dividend for shareholders and taxed at the applicable rate for each shareholder. In addition, the Commissioner has declined to provide Perpetual with a binding ruling that Part IVA will not apply and has also indicated that it cannot rule out that it will apply Part IVA. What's the damage? The ASX 200 stock notes that if the above were to apply, the assessed primary tax liability for Perpetual is estimated to be $488 million, without including any additional penalties and interest. This is significantly more than its previous estimate of $106 million to $227 million. As a result, the estimated cash proceeds to shareholders for the transaction would reduce from between $8.38 and $9.82 per share, as previously announced, to just $5.74 to $6.42 per share. Extremely disappointed In response to the news, the company said: Perpetual is extremely disappointed and disagrees with the Commissioner's views. Based on strong advice from relevant tax experts, including Senior Counsel, and following extensive Board testing and consideration, Perpetual continues to be of the view that the provisions should not apply. In Perpetual's assessment of the Scheme, it noted numerous previous scheme transactions that had been undertaken in a similar manner. However, it concedes that it may not be able to appeal the ruling given the impact it could have on the transaction and capital return. It adds: Perpetual considers it has strong grounds to dispute this position. However, to do so, Perpetual would need to withhold sufficient funds to cover the ATO's asserted corporate tax liability amount from any shareholder proceeds under the Scheme until completion of that process, which would be protracted, would only commence once Perpetual was assessed and there would be no certainty of the outcome. Perpetual and KKR are now engaging to consider the potential impact on the transaction. Is the transaction in danger? In recent days, Bell Potter suggested that this tax ruling could put the transaction at risk if it were not favourable. Though, it doesn't necessarily see this as a bad outcome. It said: If the ATO are pushing for more than $227m, then this should be put to shareholders, who could potentially vote against the Scheme. This might sound bad, but the equity market is now around 10% higher than it was in May, when KKR's price of $2,175m was agreed. These are good businesses and given the market, should be worth more now. Retaining them, and the Perpetual brand may be a preferable outcome to paying more than $227m in tax to the ATO.